Introduction
============

Neuropathic pain (NP) is a chronic pain condition that is often caused by damage to the somatosensory system, such as that observed with spinal cord injury (SCI).[@b1-jpr-11-2331] NP is prevalent in up to 80% of the persons with SCI, which contributes to suffering and a low quality of life.[@b2-jpr-11-2331] Managing NP in SCI subjects is clinically challenging, partly because the underlying mechanisms of this condition are multifactorial in nature and have yet to be clearly delineated.[@b3-jpr-11-2331],[@b4-jpr-11-2331] Rather, the precise pathophysiology of chronic NP after SCI is controversial with many differing theories in existence. Conventional thought based on historical findings suggests that NP originates at the level of the SCI.[@b3-jpr-11-2331],[@b4-jpr-11-2331] Moreover, there exists increasing evidence suggesting that supraspinal centers may have a vital role in NP pathogenesis.[@b5-jpr-11-2331]--[@b8-jpr-11-2331] Furthermore, numerous recent studies have also demonstrated associations between these supraspinal centers and the central autonomic network (CAN) in the context of NP generation after SCI.[@b8-jpr-11-2331]--[@b11-jpr-11-2331] However, these proposed autonomic correlates to NP after SCI have been less investigated.

Following a landmark series of studies, Melzack et al[@b12-jpr-11-2331]--[@b14-jpr-11-2331] identified a pain neuromatrix (PNM) composed of numerous cortical and subcortical structures responsible for mediating the multidimensional nature of pain. Functional MRI (fMRI) investigations have supported these findings by demonstrating increased activity diffusely across the PNM structures of healthy controls after induction of painful stimuli.[@b5-jpr-11-2331],[@b6-jpr-11-2331] These structures are varied and extensive; the most implicated areas include the insular cortex, anterior cingulate cortex, posterior parietal cortex, prefrontal cortex, and thalamus.[@b5-jpr-11-2331],[@b6-jpr-11-2331] Interestingly, similar fMRI approaches found that pain induction in persons with chronic SCI increased the activity in certain PNM regions to a greater extent as in healthy controls.[@b8-jpr-11-2331] These SCI-specific regions of increased activity included regions of the insular cortex, anterior cingulate cortex, and prefrontal cortex.[@b8-jpr-11-2331] In particular, these pain-specific PNM regions in persons with chronic SCI were highly associated and shared much overlap with the CAN.[@b8-jpr-11-2331] Their relations are schematically represented in [Figure 1](#f1-jpr-11-2331){ref-type="fig"}.[@b5-jpr-11-2331]--[@b11-jpr-11-2331]

These findings support the fact that NP after chronic SCI may be the result of maladaptive neuroplasticity and central sensitization occurring at the supraspinal level and that these alterations may be the resultant of injury chronicity.[@b3-jpr-11-2331],[@b4-jpr-11-2331],[@b7-jpr-11-2331]--[@b9-jpr-11-2331],[@b15-jpr-11-2331] Moreover, it can also be suggested that autonomic activity may represent a surrogate measure to detect NP activity, as produced via the shared PNM--CAN, and prove to be useful in NP diagnostics in SCI populations.[@b8-jpr-11-2331]--[@b11-jpr-11-2331]

Heart rate variability (HRV), the physiological variance in the interbeat interval, is an increasingly documented modality for quantifying autonomic activity and thus reflecting CAN function.[@b16-jpr-11-2331],[@b17-jpr-11-2331] Numerous studies have even characterized HRV differences in subjects with various acute and chronic pain syndromes that include but are not limited to irritable bowel syndrome, lower back pain, fibromyalgia, and so on.[@b18-jpr-11-2331]--[@b22-jpr-11-2331] Koenig et al[@b23-jpr-11-2331] have also established that HRV parameters can capture diminished parasympathetic influence with induction of experimental pain in healthy adults. We recently published an innovative study that evidenced the capacity of baseline HRV parameters, namely time domain variables, to differentiate chronic SCI subjects with and without NP.[@b24-jpr-11-2331] Additionally, we demonstrated that those HRV differences were unlikely to be influenced by the neurologic level or severity of the SCI itself.[@b24-jpr-11-2331]

In this study, we intended to further explore modulation of chronic NP following SCI as detected by HRV changes. Essentially, we aimed to explore the utility of HRV differences to capture acute autonomic responses to treatment of chronic NP following SCI. To investigate this, we utilized centrally directed NP analgesia to measure changes in CAN activity. Breathing-controlled electrical stimulation (BreEStim) is a novel non-invasive intervention using electrical stimulation (EStim) that is triggered by voluntary breathing and delivered to a peripheral nerve transcutaneously. BreEStim has been shown to be effective for the treatment of chronic NP following SCI.[@b25-jpr-11-2331],[@b26-jpr-11-2331] Moreover, we have also presented evidence suggesting that BreEStim operates via selective modulation of various cortical and subcortical structures responsible for voluntary respiration and noxious stimuli processing.[@b27-jpr-11-2331]--[@b29-jpr-11-2331] These neural structures are explicably the same components utilized in the PNM machinery and thus also the shared PNM--CAN. We hypothesized that centrally directed NP analgesia via BreEStim would affect PNM--CAN activity, and thus HRV measures, in persons with chronic NP following SCI. As such, BreEStim-induced analgesia was hypothesized to be accompanied by restoration of automatic dysfunctions in these persons with NP following SCI as seen in our study.[@b24-jpr-11-2331] In particular, we hypothesized that those HRV parameters produced by time domain analysis would be sensitive to parasympathetic tone changes associated with NP and with BreEStim treatment for NP.

Methods
=======

Subject population
------------------

This study was conducted with the necessary approvals and recommendations of the University of Texas Health Sciences Center at Houston institutional review board. All subjects were recruited at our outpatient specialty SCI rehabilitation clinic, located in an academic setting. Inclusion and exclusion criteria for the study were as follows: 1) persons with capacity of providing consent, 2) who were between 18 and 75 years of age, 3) with an SCI for \>6 months, 4) without clinically significant or unstable medical or neuropsychiatric disorders, 5) without a history of intracranial pathology, such as traumatic brain injury, stroke, or brain tumors, 6) without a history of intracranial intervention or surgery, 7) without a history of cardiac pathology or implanted pacemakers, 8) without the current usage of inotropic or chronotropic medications, such as beta-blockers, that may artificially alter the heart rate and/or rhythm, and 9) on a stable pain medication regimen, if needed, for at least 2 weeks prior to the experiment. All subjects provided written informed consent prior to the experiments.

A physician with subspecialty training and board certification in SCI medicine then assigned those subjects who met the primary inclusion/exclusion criteria to either SCI+NP or SCI--NP groups. Subjects in the SCI+NP group were determined to have chronic NP for \>3 months, whereas subjects in the SCI--NP group were determined to be either without pain or with a nociceptive pain condition, ie, musculoskeletal in origin. Testing was excluded from those who were suspected to have autonomic dysreflexia in the preceding 24 hours. The primary experimental portion of the study was conducted in the SCI+NP group (n=10). To further interrogate the autonomic profiles of SCI subjects with and without pain, the SCI+NP group was then compared with the SCI--NP group (n=11). Of note, both SCI groups comprise a subset of subjects from our prior study exploring baseline HRV differences between SCI+NP and SCI--NP groups.[@b24-jpr-11-2331]

VAS scoring and HRV collection
------------------------------

For SCI--NP subjects, HRV data were only collected at resting baseline (BS SCI--NP). For SCI+NP subjects, VAS scores and HRV data were collected at resting baseline (BS SCI+NP or pre-test SCI+NP) and at 30 minutes following the intervention (post-test SCI+NP). At both time points, the subjects were asked to rate their current pain level using the VAS pain scoring system, which designates scores from 0 through 10, with "0" described as no pain and a score of "10" described as agonizing, distressing, and/or the worst pain ever felt. Following pain reporting, the subjects were prepared for electrocardiogram (ECG) collection for HRV analysis and given a 5-minute resting period. After the skin was cleaned with an alcohol wipe to ensure appropriate electrode contact, disposable adhesive electrodes attached to ECG leads were placed on the subject's chest. The white "right arm" and black "left arm" electrodes were placed in the first intercostal spaces along the midclavicular lines on the right and left chest wall, respectively. The red "left leg" electrode was placed in the lower intercostal spaces along the left mid-axillary line. After instructing subjects to remain calm, seated, and relaxed with limited movement, a 5-minute ECG recording was collected using a heart rhythm scanner (Biocom 5000 Wireless ECG Recorder; Biocom Technologies, Poulsbo, WA, USA). ECG heart rhythms were saved for off-line HRV analysis. The same ECG recording protocol was used as in our recent study.[@b24-jpr-11-2331]

Breathing only (null) and BreEStim (active) interventions
---------------------------------------------------------

All SCI+NP subjects participated in two experiments, which were administered in a random order, on different days, and at least 3 days apart. In Experiment 1 (null), a total of 120 voluntary, paced breaths were administered to subjects. In Experiment 2 (active), a total of 120 electrical stimuli during BreEStim were delivered to all subjects. Note that both the null and active interventions were each only performed once for each subject.

For Experiment 1 (null), subjects were seated comfortably and fitted with a leak-proof face mask, which was connected to a Pneumotach system (Hans Rudolph Inc., Shawnee, KS, USA) to record the airflow rate. Subjects were instructed to breathe using fast, strong, and deep inhalations. Data from the Pneumotach apparatus were displayed on the computer screen to ensure sufficient inhalation effort. After a brief training tutorial, a total of 120 breaths meeting experimental criteria were conducted.

For Experiment 2 (active), subjects followed the same protocol for deep, voluntary breathing as described earlier. Additionally, a pair of trimmed surface electrodes \~2 cm×2 cm separated bŷ1 cm was placed over the ventral aspect of the distal forearm along the path of the median nerve. A single pulse (0.1 ms square wave) of EStim was delivered to the median nerve transcutaneously when the airflow rate reached the preset threshold level of 40% peak rate. This occurred when subjects took a fast, strong, and deep inhalation as instructed. Subjects were encouraged to gradually increase the intensity of EStim, before the halfway point of 60 breaths, to a painful yet tolerable pain level equivalent to a VAS score of 7--8. Subjects were explicitly instructed that EStim averseness was important for the BreEStim intervention. After a brief training tutorial, a total of 120 breathing-mediated EStim impulses were delivered.

Prior to the intervention in both experiments, subjects had a familiarization session to ensure that they understood the equipment, procedure, and requirements. For each treatment session that lasted \~30 minutes, the subjects were encouraged and allowed to take breaks to ensure sufficient rest. These settings and protocols were similar to our recent series of BreEStim experiments, which include studies evidencing BreEStim as an effective analgesic intervention of NP associated with SCI.[@b25-jpr-11-2331] Further technical details of BreEStim are available online in a methodology video article: <http://www.jove.com/video/50077/.1>

Data analysis
-------------

All demographic data were provided by the subjects. Clinical variables, particularly those relevant to the SCI, were gathered from the most recent International Standards for Neurological Classification of SCI examination documented by a physician with specialty training and board certification in SCI medicine. Relevant SCI-associated clinical variables gathered included the date of the injury, neurologic injury level, and severity of injury. Active prescription medications were surveyed in the electronic health record to determine the type, frequency, and dosage of NP medications being used. NP medications were assigned to categories of GABA analogs, which include gabapentin and pregabalin, atypical antidepressants, which include tricyclic antidepressants (TCA) and serotonin--norepinephrine reuptake inhibitors (SNRI), or opiates. As is conventional for quantifying opiates in scientific publications, daily morphine equivalents are reported.[@b30-jpr-11-2331]

Kubios HRV analysis software (University of Eastern Finland, Joensuu, Finland) was used to evaluate the ECG recording.[@b31-jpr-11-2331] The heart rhythms were analyzed via time and frequency domain approaches to obtain various HRV parameters.[@b21-jpr-11-2331]--[@b24-jpr-11-2331] The time domain parameters include SD of the normal-to-normal intervals (SDNN), root mean squared of successive differences (RMSSD), pairs of successive R--R beat lengths varying by greater than 50 ms (NN50), and proportion of NN50 for total number of beats (pNN50). SDNN reflects overall HRV, whereas RMSSD, NN50, and pNN50 reflect parasympathetic tone. The frequency domain parameters include low frequency (LF) band, high frequency (HF) band, total power, and low to high frequency ratio (LF/HF). Standard frequency stratification designating LF as 0.04--0.15 Hz and HF as 0.15--0.40 Hz, as determined by the fast Fourier transformation algorithm, was utilized. LF is an LF spectral component representing sympathetic-driven (baroreflex-mediated) vagal outflow, HF reflects parasympathetic tone, and total power reflects overall HRV, whereas LF/HF reflects degree of autonomic balance.

Statistical analyses
--------------------

Statistical analyses were performed similar to those described in our recent publication.[@b24-jpr-11-2331] The major dependent variables were as follows: 1) VAS scores, 2) average HR, and 3) mean R--R length; the major HRV-dependent variables from the time domain analysis were as follows: 1) SDNN, 2) RMSSD, 3) NN50, and 4) pNN50; the major HRV-dependent variables from frequency domain analysis were as follows: 1) LF, 2) HF, 3) total power, and 4) LF/HF. We chose to analyze 1) demographics and SCI parameters for SCI+NP vs SCI--NP groups, 2) BS SCI+NP vs post-test SCI+NP groups for both null and active experiments, 3) the change between BS SCI+NP and post-test SCI+NP values across null or active experiments, and 4) BS SCI+NP active group vs post-test SCI+NP active group vs BS SCI--NP group.

For use in statistical analyses, all HRV parameters, expect SDNN, are non-normally distributed. For two group comparisons of similar groups, paired *t*-tests and Wilcoxon signed-rank tests were used for parametric and non-parametric variables, respectively. For two group comparisons of non-similar groups, independent samples *t*-tests and Mann--Whitney *U* tests were used for parametric and non-parametric variables, respectively. Two-way ANOVA tests and the Kruskal--Wallis tests with Scheirer--Ray--Hare extension were conducted to measure the interaction of time (BS and post-test) and treatment (null and active) factors in producing changes in parametric and non-parametric variables, respectively.

Statistical analysis was performed using the STATA Version 12.1 (StataCorp LP, College Station, TX, USA). An alpha level of 0.05 was used as threshold for significance for all statistical tests. Data were reported as mean±SD within the text and as mean±standard error of the mean (SEM) in the figures. Only the significant main effects were presented, unless otherwise noted.

Results
=======

Study subjects
--------------

Our study cohort included 21 predominantly male, middle-aged subjects with SCI, who were dichotomized into SCI+NP (n=10) or SCI--NP (n=11) groups ([Tables 1](#t1-jpr-11-2331){ref-type="table"} and [2](#t2-jpr-11-2331){ref-type="table"}). Both groups were similar in age, gender, and SCI-relevant clinical parameters, which include duration of injury, tetraplegia (C8 and above), T4 and above injuries, and complete injury prevalence ([Table 3](#t3-jpr-11-2331){ref-type="table"}). The clinically relevant cutoffs of C8 and above, and T4 and above, were chosen to reveal the number of persons in our study cohort with tetraplegia and disrupted sympathetic innervation to the heart, respectively.

In regard to NP treatment, most SCI+NP subjects were utilizing pain medications. The most commonly utilized medications were the GABA analogs, gabapentin (n=4) and pregabalin (n=4). Three subjects used other medications -- the SNRI duloxetine (n=1) and an opioid (n=2). One patient (subject 1) was not using pain medications. In the SCI--NP group, only three subjects were using pain medications; they were using only gabapentin on an as-needed basis for indications other than NP. Regarding the interventions, all subjects tolerated treatment sessions well; no adverse events including episodes of hyperventilation or hypoxia were reported.

VAS, HRV changes for the null vs active experiments
---------------------------------------------------

The VAS scores reported during the baseline phase of both null and active interventions were comparable for SCI+NP subjects ([Table 3](#t3-jpr-11-2331){ref-type="table"} and [Figure 2A](#f2-jpr-11-2331){ref-type="fig"}). However, there was a significant interaction between the effects of time and treatment on VAS scores (*F*\[1, 36\]=4.42, *P*=0.04). Simple main effects analysis showed that VAS scores significantly decreased across time with the active treatment (*P*\<0.01), but there were no differences across time with the null treatment.

The recorded mean HR and R--R length were comparable across both time and interventions. In regard to HRV time domain parameters, however, several key differences were appreciated ([Table 3](#t3-jpr-11-2331){ref-type="table"} and [Figure 2B--D](#f2-jpr-11-2331){ref-type="fig"}). Parasympathetic tone, as measured by NN50 and pNN50, was found to profoundly increase across time only for the active intervention. There was a significant interaction between the effects of time and treatment for both parameters (NN50: *F*\[1, 36\]=4.92, *P*=0.03; pNN50: *F*\[1, 36\]=4.57, *P*=0.04). Simple main effects analysis showed that the values of both parameters significantly increased across time with active treatment (NN50: *P*=0.03; pNN50: *P*=0.02), but there were no differences across time with null treatment. HRV frequency domain parameters did not change across time for either null or active treatments ([Table 4](#t4-jpr-11-2331){ref-type="table"}).

SCI+NP active treatment response vs SCI--NP baseline
----------------------------------------------------

To examine whether HRV parameters were restored after BreEStim along with the analgesic effects, we compared heart rhythm and HRV parameters for the active BS (or pre-test) SCI+NP group and the active post-test SCI+NP group each vs the BS SCI--NP group. There were no differences in the baseline heart rhythm for either group comparison ([Table 5](#t5-jpr-11-2331){ref-type="table"}). In comparing HRV time domain parameters, however, the active pre-test SCI+NP group was found to have a lower HRV than the baseline SCI--NP group (*P*=0.01) ([Table 5](#t5-jpr-11-2331){ref-type="table"} and [Figure 3](#f3-jpr-11-2331){ref-type="fig"}), as determined by SDNN. For all other time domain parameters, both the SCI+NP groups were found to be comparable to the SCI--NP group. Additionally, HRV frequency domain analysis revealed the active pre-test SCI+NP group to have a lower overall HRV than the baseline SCI--NP group (*P*\<0.05), as determined by LF ([Table 5](#t5-jpr-11-2331){ref-type="table"} and [Figure 4](#f4-jpr-11-2331){ref-type="fig"}). For all other frequency domain parameters, both the SCI+NP groups were found to be comparable to the SCI--NP group. Taken together, these comparisons suggested acute restoration of some autonomic function after the active treatment with BreEStim.

Discussion
==========

We have recently reported novel findings demonstrating the capability of certain baseline time domain HRV parameters to reflect autonomic aberrations specifically associated with chronic NP in an SCI cohort.[@b24-jpr-11-2331] Additionally, the findings suggested that those distinct HRV disparities were unlikely to be influenced by the neurological level of injury or SCI status itself. This succeeding study characterizes the capacity of HRV parameters to reflect autonomic restoration in response to a centrally targeted analgesic intervention in a cohort of subjects with SCI and chronic NP, concomitantly with analgesic effects. As such, the current findings further highlight central autonomic influences in the context of the supraspinal PMN--CAN-associated pathogenesis of chronic NP after SCI.

The crossover study design provided both null and active analgesic interventions, in a random order, to all subjects in the SCI+NP group. The experimental group of SCI+NP subjects was similar to our SCI--NP cohort in demographics and SCI clinical characteristics ([Table 3](#t3-jpr-11-2331){ref-type="table"}). The novel and unique findings in this study were that certain HRV parameters, namely NN50 and pNN50, were able to capture the increase in parasympathetic tone following active analgesic intervention ([Table 4](#t4-jpr-11-2331){ref-type="table"}, [Figures 3](#f3-jpr-11-2331){ref-type="fig"} and [4](#f4-jpr-11-2331){ref-type="fig"}). The increases in parasympathetic modulation across time were specific for active intervention and were associated with patient-reported analgesic effect. Additionally, other HRV parameters demonstrated baseline differences in autonomic profiles between SCI+NP and SCI--NP subjects ([Table 5](#t5-jpr-11-2331){ref-type="table"}, [Figures 3](#f3-jpr-11-2331){ref-type="fig"} and [4](#f4-jpr-11-2331){ref-type="fig"}). Namely, SCI+NP subjects were found to exhibit a lower overall HRV and parasympathetic tone compared with SCI--NP subjects, as determined by lower values of SDNN and LF, respectively. Following active intervention, however, we observed that SCI+NP subjects displayed an increased overall HRV and parasympathetic tone ([Table 4](#t4-jpr-11-2331){ref-type="table"}, [Figures 3](#f3-jpr-11-2331){ref-type="fig"} and [4](#f4-jpr-11-2331){ref-type="fig"}). This autonomic restoration, specific to active intervention, is associated with NP analgesic treatment response. Furthermore, the SCI+NP subjects following active intervention were found to be comparable to SCI--NP subjects regarding heart rhythm variability time and frequency domain parameters.

Sensitivity of time domain HRV parameters
-----------------------------------------

These collective findings led us to suspect that there may be a degree of sensitivity for various HRV parameters. In other words, just as SDNN and LF were apt at measuring baseline differences between SCI+NP and SCI--NP subjects, they may not be sensitive to capturing acute changes in autonomic activity. Similarly, the NN50 and pNN50 variables, which were unable to differentiate baseline differences between SCI--NP and SCI+NP groups, were capable of measuring active treatment response. Thus, NN50 and pNN50 may be much more sensitive to acute changes in autonomic activity relative to chronic changes. The phenomenon of HRV changes during acute vs chronic stress has been reported in both human and animal studies.[@b32-jpr-11-2331]--[@b34-jpr-11-2331] Moreover, these studies also find overall interbeat variance, SDNN, to be more susceptible to chronic stressors. Our recent studies further support sensitivity of time domain HRV parameters from 5-minute ECG recordings in capturing autonomic dysfunction after SCI.[@b35-jpr-11-2331],[@b36-jpr-11-2331] For example, as compared to frequency domain HRV parameters, SDNN/NN50 were able to better track autonomic responses to transcutaneous tibial nerve stimulation of neurogenic bladder based on urodynamic outcomes.[@b35-jpr-11-2331],[@b36-jpr-11-2331]

BreEStim modulation of NP after SCI is associated with restoration of autonomic dysfunction
-------------------------------------------------------------------------------------------

Our finding of active treatment response associated with an increase in parasympathetic tone can be supported by the normal mechanisms of the CAN machinery. In the absence of pain pathology, the CAN acts to regulate the sympathetic and parasympathetic output in response to the physiological environment.[@b37-jpr-11-2331],[@b38-jpr-11-2331] Numerous studies exploring HRV changes in the healthy adults found that a robust parasympathetic tone was a marker of healthy status.[@b23-jpr-11-2331],[@b38-jpr-11-2331]--[@b40-jpr-11-2331] These findings are congruent with our study with decreased parasympathetic tone in persons with concomitant SCI and NP relative to persons with SCI but without NP or healthy persons.[@b24-jpr-11-2331] Therefore, it follows that the decreased parasympathetic tone in persons with SCI and NP may be secondary to altered mechanisms in the pathological CAN, which may be absent in persons with SCI and without NP and healthy persons.

The central thrust of this study -- that NP modulations after SCI have supraspinal origins that are strongly associated with central autonomic pathogenesis -- can also be substantiated by recent advances in the understanding of NP following amputation. Just as implicated in SCI, central neuroplastic changes have also been suggested to drive the pathogenesis of NP following amputations.[@b41-jpr-11-2331],[@b42-jpr-11-2331] Namely, the similar fMRI studies used to interrelate NP and SCI have also shown strong cortical and subcortical restructuring patterns in persons with NP after amputation, including structures involved in autonomic modulation. Even further, treating phantom pain has been found to correlate with the degree of somatosensory smudging.[@b43-jpr-11-2331] These similarities of supraspinal modulation of NP after SCI (injury at the central nervous system) and amputation (injury of the peripheral nerves) are further evidenced by reports of BreEStim providing efficacious analgesic effect despite treating both conditions via peripherally driven stimulation at the median nerve, rather than the injury foci.[@b25-jpr-11-2331],[@b44-jpr-11-2331] Moreover, because BreEStim to the median nerve on one side has also been shown to alter pain threshold capacity on both sides in healthy persons, it is thought to modulate activity at the central level, likely including the PNM. In the context of our current study, the extensively established BreEStim intervention for supraspinal analgesia substantiates our theorized paradigm schematically represented in [Figure 1](#f1-jpr-11-2331){ref-type="fig"}. Furthermore, the analgesia-associated autonomic changes as quantified by HRV in this study serve to demonstrate the interconnected PNM--CAN machinery.[@b10-jpr-11-2331],[@b11-jpr-11-2331]

Additionally, the mechanistic actions of GABA analog medications also serve to further substantiate our findings. GABA analog medications, including gabapentin and pregabalin, are first-line treatments for NP.[@b45-jpr-11-2331] Gabapentin has been demonstrated to act by increasing the spinal-derived parasympathetic outflow by way of inhibiting glutamatergic transmission.[@b46-jpr-11-2331],[@b47-jpr-11-2331] Additionally, pregabalin functions by decreasing the release of norepinephrine, among other neurotransmitters, to ameliorate sympathetically modulated pain processes.[@b48-jpr-11-2331],[@b49-jpr-11-2331] Consequently, our findings suggest that increases in parasympathetic tone, as determined by HRV, may be correlated with analgesic perception. Collectively, our findings provide experimental evidence supporting the notion that chronic NP in persons with SCI is likely to be modulated at the supraspinal level.

Limitations
-----------

The primary limitation of this study was a small sample size; this study was powered primarily based on sample sizes of convenience. As such, further analyses exploring the impact of the neurological level of injury on HRV modulations after intervention were prevented. Findings from this work will help future studies in estimating the appropriate power and sample sizes required. Future higher powered studies exploring HRV changes associated with different NP treatments would provide useful information regarding the autonomic pathophysiology of NP-associated analgesia. Additionally, the use of fMRI in conjunction to analgesic experiments in subjects with SCI and NP may provide instrumental knowledge regarding neural activity in PNM--CAN.

Of note, many experimental pain studies including this study utilize a 5-minute ECG approach for HRV analysis for logistical ease. However, it has been suggested that frequency domain parameters may be more appropriately sensitive with longer recordings, including 24-hour ECG monitoring.[@b16-jpr-11-2331],[@b17-jpr-11-2331] Regardless, studies have shown that the capacity of frequency domain parameters extrapolated 5-minute ECG to reflect chronic pain, which substantiated the use of a 5-minute ECG approach in this study.[@b19-jpr-11-2331]--[@b22-jpr-11-2331] Finally, restoration of autonomic dysfunction was observed concomitantly with analgesic effects after only one session of BreEStim treatment. It would be important to know for future clinical use whether this effect will be accumulated and sustained after long-term BreEStim treatment.

Conclusion
==========

Increasing evidence suggests that supraspinal modulation of chronic NP after SCI is highly associated with central autonomic circuitry. However, the role of autonomic correlates associated in this context has been less investigated. In an experimental model, we found that centrally delivered analgesia, as provided by BreEStim, in a cohort of persons with chronic NP and SCI is associated with autonomic restoration, as measured by HRV changes. Our results provide investigational evidence supportive of the high degree of interconnectedness between the PNM and the CAN in modulating chronic NP following SCI and NP response to neuromodulatory interventions, such as BreEStim.
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![Schematic depicting the proposed relationship among the PNM and the CAN.\
**Notes:** (**A**) Upon pain induction, the PNM is diffusely activated. It is susceptible to BreEStim influence. (**B**) The PNM--CAN of shared structures is specifically activated in chronic SCI. (**C**) The CAN helps regulate the autonomic system. BreEStim is hypothesized to modulate the PNM, including the shared PNM--CAN areas, to produce analgesic effects, and thus changes in HRV parameters as well.\
**Abbreviations:** BreEStim, breathing-controlled electrical stimulation; CAN, central autonomic network; HRV, heart rate variability; PNM, pain neuromatrix; SCI, spinal cord injury.](jpr-11-2331Fig1){#f1-jpr-11-2331}

![The changes in various parameters across pre-test and post-test time points for null and active experiments in the SCI+NP study group (n=10).\
**Notes:** Parameters displayed include (**A**) VAS, (**B**) SDNN, (**C**) NN50: pairs of successive R--R beat lengths varying by greater than 50 ms, and (**D**) pNN50: proportion of NN50 for total number of beats. Standard error bars are shown; asterisk denotes statistically significant differences.\
**Abbreviations:** NP, neuropathic pain; SCI, spinal cord injury; SDNN, SD of the normal-to-normal intervals.](jpr-11-2331Fig2){#f2-jpr-11-2331}

![The values of the HRV time domain parameters for the active pre-test, active post-test, and SCI--NP baseline tests are shown.\
**Notes:** Time domain parameters displayed include SDNN, RMSSD, NN50: pairs of successive R--R beat lengths varying by greater than 50 ms, and pNN50: proportion of NN50 for total number of beats. SDNN reflects overall HRV, whereas RMSSD, NN50, and pNN50 reflect parasympathetic tone. Standard error bars are shown; asterisk denotes statistically significant differences.\
**Abbreviations:** HRV, heart rate variability; NP, neuropathic pain; RMSSD, root mean squared of successive differences; SCI, spinal cord injury; SDNN, SD of the normal-to-normal intervals.](jpr-11-2331Fig3){#f3-jpr-11-2331}

![The values of the frequency domain parameters for the active pre-test, active post-test, and SCI--NP baseline tests are shown.\
**Note:** Frequency domain parameters displayed include LF band, HF band, total power, and LF/HF. Standard error bars are shown; asterisk denotes statistically significant differences.\
**Abbreviations:** HF, high frequency; LF, low frequency; LF/HF, low to high frequency ratio; NP, neuropathic pain; SCI, spinal cord injury.](jpr-11-2331Fig4){#f4-jpr-11-2331}

###### 

Pertinent demographics, SCI-relevant parameters, and pain medications, along with their milligram dosage and frequency, of each patient in the SCI+NP study group

  Subject   Age   Gender   Years since injury   Injury level, AIS score   GABA analogs        Atypical antidepressants   Daily morphine equivalents
  --------- ----- -------- -------------------- ------------------------- ------------------- -------------------------- ----------------------------
  1         55    M        9                    C4, C                     N/A                 N/A                        N/A
  2         47    M        11                   C5, C                     Gabapentin 600q8h   N/A                        N/A
  3         54    M        37                   C5, C                     Gabapentin 300q8h   N/A                        N/A
  4         59    M        8                    C5, D                     Gabapentin 600q8h   N/A                        N/A
  5         56    M        9                    C6, C                     Pregabalin 75q8h    N/A                        60
  6         50    M        27                   C6, D                     N/A                 N/A                        As needed, 5--10
  7         31    M        16                   C7, B                     Gabapentin 300q8h   N/A                        N/A
  8         20    M        2                    L1, A                     Pregabalin 25q12h   N/A                        N/A
  9         61    M        4                    L1, A                     Pregabalin 50q12h   N/A                        N/A
  10        49    M        10                   L2, D                     Pregabalin 150q8h   Duloxetine 60q24h          N/A

**Abbreviations:** AIS, American spinal injury association impairment scale; F, female; M, male; NP, neuropathic pain; SCI, spinal cord injury.

###### 

Pertinent demographics, SCI-relevant parameters, and pain medications, along with their milligram dosage, frequency, and indication, of each patient in the SCI--NP study group

  Subject   Age   Gender   Years since injury   Injury level, AIS score   Pain medications      Indication for medication
  --------- ----- -------- -------------------- ------------------------- --------------------- -----------------------------
  1         37    M        17                   C4, B                     N/A                   N/A
  2         46    M        1.5                  C5, C                     N/A                   N/A
  3         19    F        1                    C7, C                     N/A                   N/A
  4         35    M        16.5                 C8, A                     N/A                   N/A
  5         21    F        2.5                  T2, A                     Gabapentin 300 q8h    As needed, for menses
  6         22    M        4.5                  T4, C                     N/A                   N/A
  7         61    M        40                   T8, B                     N/A                   N/A
  8         64    M        20                   T9, D                     N/A                   N/A
  9         48    M        8.5                  T12, A                    N/A                   N/A
  10        25    M        3                    T11, C                    Gabapentin 300 q8h    As needed, for constipation
  11        46    F        11                   T12, C                    Gabapentin 100 q12h   As needed, for menses

**Abbreviations:** AIS, American spinal injury association impairment scale; F, female; M, male; NP, neuropathic pain; SCI, spinal cord injury.

###### 

Pertinent demographics and SCI-relevant parameters of the SCI+NP and SCI--NP study groups

                        SCI+NP (N=10)   SCI--NP (N=11)   *P*-Value
  --------------------- --------------- ---------------- -----------------
  Demographics                                           
  Age (years)           48.2            38.6             0.146, T=--1.52
  Male (%)              100.0           70.0             0.308, T=−1.52
  SCI parameters                                         
  Years since injury    13.3            11.4             0.705, T=−0.38
  C8 and above (%)      70.0            36.4             0.136, T=−1.56
  T4 and above (%)      70.0            54.6             0.491, T=−0.70
  Complete injury (%)   20.0            27.3             0.713, T=0.37

**Abbreviations:** NP, neuropathic pain; SCI, spinal cord injury.

###### 

VAS scores, heart rhythm, and time domain and frequency domain parameters of the SCI+NP study group[a](#tfn4-jpr-11-2331){ref-type="table-fn"}

                                          Null     Active   Two-way ANOVA                               
  --------------------------------------- -------- -------- --------------- -------- ---------- ------- -----------------
  Subjective pain                                                                                       
  VAS scores                              4.15     3.90     0.789           4.30     1.63       0.003   0.043, 4.42
  Baseline heart rhythm                                                                                 
  Average heart rate (beats per minute)   78.94    77.05    0.568           78.53    75.83      0.462   0.939, 0.01
  Mean R--R length (ms)                   783.82   808.93   0.568           790.24   826.31     0.462   0.910, 0.01
  Time domain parameters                                                                                
  SDNN (ms)                               32.73    42.76    0.870           28.77    39.47      0.165   0.967, 0.00
  RMSSD (ms)                              18.78    39.66    0.897           20.44    30.31      0.153   0.655, 0.20
  NN50 (count)                            11.20    9.56     0.931           7.50     30.22      0.030   0.033, 4.92
  pNN50 (%)                               2.86     2.99     0.931           2.29     9.88       0.023   0.040, 4.57
  Frequency domain parameters                                                                           
  LF power (ms[@b2-jpr-11-2331])          162.20   279.67   0.327           115.80   181.67     0.369   0.649, 0.21
  HF power (ms[@b2-jpr-11-2331])          129.20   107.89   0.935           212.00   230.11     0.935   0.747, 0.11
  Total power (ms[@b2-jpr-11-2331])       729.30   620.56   0.959           695.30   1,275.11   0.253   0.133, *F*=2.37
  LF/HF                                   2.00     4.75     0.121           2.25     2.67       0.369   0.307, 1.08

**Notes:**

Values obtained during baseline and post-test time points during the null and active experiments. NN50: pairs of successive R--R beat lengths varying by greater than 50 ms and pNN50: proportion of NN50 for total number of beats.

**Abbreviations:** HF, high frequency; LF, low frequency; LF/HF, low to high frequency ratio; NP, neuropathic pain; RMSSD, root mean squared of successive differences; SCI, spinal cord injury; SDNN, SD of the normal-to-normal intervals.

###### 

Heart rhythm, time domain parameters, and frequency domain parameters of the SCI+NP group during baseline and post-test time points and the SCI--NP group at baseline

                                          1        2          3          1 vs 3   2 vs 3
  --------------------------------------- -------- ---------- ---------- -------- --------
  Baseline heart rhythm                                                           
  Average heart rate (beats per minute)   78.53    75.83      63.59      0.072    0.129
  Mean R--R length (ms)                   790.24   826.31     982.51     0.081    0.110
  Time domain parameters                                                          
  SDNN (ms)                               28.77    39.47      60.15      0.010    0.222
  RMSSD (ms)                              20.44    30.31      43.43      0.114    0.881
  NN50 (count)                            7.50     30.22      38.73      0.258    0.674
  pNN50 (%)                               2.29     9.88       13.51      0.230    0.646
  Frequency domain parameters                                                     
  LF power (ms[@b2-jpr-11-2331])          115.80   181.67     783.91     0.045    0.159
  HF power (ms[@b2-jpr-11-2331])          212.00   230.11     714.23     0.289    0.197
  Total power (ms[@b2-jpr-11-2331])       695.30   1,275.11   1,833.00   0.803    0.596
  LF/HF                                   2.25     2.67       1.36       0.308    0.764

**Notes:**

NN50: pairs of successive R--R beat lengths varying by greater than 50 ms and pNN50: proportion of NN50 for total number of beats.

**Abbreviations:** HF, high frequency; LF, low frequency; LF/HF, low to high frequency ratio; NP, neuropathic pain; RMSSD, root mean squared of successive differences; SCI, spinal cord injury; SDNN, SD of the normal-to-normal intervals.
